Literature DB >> 28380622

Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans.

Lu Liu1, Raffael Nachbagauer2, Lingyan Zhu1, Yang Huang1, Xinci Xie1, Shan Jin1, Anli Zhang1, Yanmin Wan1, Ariana Hirsh2, Di Tian1, Xiaolin Shi3, Zhaoguang Dong1, Songhua Yuan1, Yunwen Hu1, Florian Krammer2, Xiaoyan Zhang1, Jianqing Xu1.   

Abstract

Background: The outbreak of novel avian H7N9 influenza virus infections in China in 2013 has demonstrated the continuing threat posed by zoonotic pathogens. Deciphering the immune response during natural infection will guide future vaccine development.
Methods: We assessed the induction of heterosubtypic cross-reactive antibodies induced by H7N9 infection against a large panel of recombinant hemagglutinins and neuraminidases by quantitative enzyme-linked immunosorbent assay, and novel chimeric hemagglutinin constructs were used to dissect the anti-stalk or -head humoral immune response.
Results: H7N9 infection induced strong antibody responses against divergent H7 hemagglutinins. Interestingly, we also found induction of antibodies against heterosubtypic hemagglutinins from both group 1 and group 2 and a boost in heterosubtypic neutralizing activity in the absence of hemagglutination inhibitory activity. Kinetic monitoring revealed that heterosubtypic binding/neutralizing antibody responses typically appeared and peaked earlier than intrasubtypic responses, likely mediated by memory recall responses. Conclusions: Our results indicate that cross-group binding and neutralizing antibody responses primarily targeting the stalk region can be elicited after natural influenza virus infection. These data support our understanding of the breadth of the postinfection immune response that could inform the design of future, broadly protective influenza virus vaccines.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  H7N9; cross-reactive antibody; influenza; stalk-reactive; universal influenza vaccine

Mesh:

Substances:

Year:  2017        PMID: 28380622      PMCID: PMC5853269          DOI: 10.1093/infdis/jiw608

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  35 in total

1.  Avian influenza A/(H7N2) outbreak in the United Kingdom.

Authors: 
Journal:  Euro Surveill       Date:  2007-05-31

2.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

3.  H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Authors:  Irina Margine; Rong Hai; Randy A Albrecht; Gerlinde Obermoser; A Carson Harrod; Jacques Banchereau; Karolina Palucka; Adolfo García-Sastre; Peter Palese; John J Treanor; Florian Krammer
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

4.  In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies.

Authors:  Nicholas S Heaton; Victor H Leyva-Grado; Gene S Tan; Dirk Eggink; Rong Hai; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

5.  An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans.

Authors:  Florian Krammer; Asne Jul-Larsen; Irina Margine; Ariana Hirsh; Haakon Sjursen; Maria Zambon; Rebecca J Cox
Journal:  Clin Vaccine Immunol       Date:  2014-06-18

6.  Human infection with a novel avian-origin influenza A (H7N9) virus.

Authors:  Rongbao Gao; Bin Cao; Yunwen Hu; Zijian Feng; Dayan Wang; Wanfu Hu; Jian Chen; Zhijun Jie; Haibo Qiu; Ke Xu; Xuewei Xu; Hongzhou Lu; Wenfei Zhu; Zhancheng Gao; Nijuan Xiang; Yinzhong Shen; Zebao He; Yong Gu; Zhiyong Zhang; Yi Yang; Xiang Zhao; Lei Zhou; Xiaodan Li; Shumei Zou; Ye Zhang; Xiyan Li; Lei Yang; Junfeng Guo; Jie Dong; Qun Li; Libo Dong; Yun Zhu; Tian Bai; Shiwen Wang; Pei Hao; Weizhong Yang; Yanping Zhang; Jun Han; Hongjie Yu; Dexin Li; George F Gao; Guizhen Wu; Yu Wang; Zhenghong Yuan; Yuelong Shu
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

Review 7.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

8.  Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands.

Authors:  Marion Koopmans; Berry Wilbrink; Marina Conyn; Gerard Natrop; Hans van der Nat; Harry Vennema; Adam Meijer; Jim van Steenbergen; Ron Fouchier; Albert Osterhaus; Arnold Bosman
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

9.  Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.

Authors:  Chao Qiu; Yang Huang; Qian Wang; Di Tian; Wanju Zhang; Yunwen Hu; Zhenghong Yuan; Xiaoyan Zhang; Jianqing Xu
Journal:  Clin Infect Dis       Date:  2011-11-03       Impact factor: 9.079

10.  Safe pseudovirus-based assay for neutralization antibodies against influenza A(H7N9) virus.

Authors:  Chao Qiu; Yang Huang; Anli Zhang; Di Tian; Yanmin Wan; Xiaoling Zhang; Wanju Zhang; Zhiyong Zhang; Zhenghong Yuan; Yunwen Hu; Xiaoyan Zhang; Jianqing Xu
Journal:  Emerg Infect Dis       Date:  2013-10       Impact factor: 6.883

View more
  21 in total

1.  Prevention and treatment of respiratory viral infections: Presentations on antivirals, traditional therapies and host-directed interventions at the 5th ISIRV Antiviral Group conference.

Authors:  Jennifer L McKimm-Breschkin; Shibo Jiang; David S Hui; John H Beigel; Elena A Govorkova; Nelson Lee
Journal:  Antiviral Res       Date:  2017-11-21       Impact factor: 5.970

Review 2.  Universal influenza virus vaccines: what can we learn from the human immune response following exposure to H7 subtype viruses?

Authors:  Daniel Stadlbauer; Raffael Nachbagauer; Philip Meade; Florian Krammer
Journal:  Front Med       Date:  2017-11-20       Impact factor: 4.592

3.  Broad Hemagglutinin-Specific Memory B Cell Expansion by Seasonal Influenza Virus Infection Reflects Early-Life Imprinting and Adaptation to the Infecting Virus.

Authors:  Brenda L Tesini; Preshetha Kanagaiah; Jiong Wang; Megan Hahn; Jessica L Halliley; Francisco A Chaves; Phuong Q T Nguyen; Aitor Nogales; Marta L DeDiego; Christopher S Anderson; Ali H Ellebedy; Shirin Strohmeier; Florian Krammer; Hongmei Yang; Sanjukta Bandyopadhyay; Rafi Ahmed; John J Treanor; Luis Martinez-Sobrido; Hana Golding; Surender Khurana; Martin S Zand; David J Topham; Mark Y Sangster
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

Review 4.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

5.  Broadly Reactive Human Monoclonal Antibodies Elicited following Pandemic H1N1 Influenza Virus Exposure Protect Mice against Highly Pathogenic H5N1 Challenge.

Authors:  Raffael Nachbagauer; David Shore; Hua Yang; Scott K Johnson; Jon D Gabbard; S Mark Tompkins; Jens Wrammert; Patrick C Wilson; James Stevens; Rafi Ahmed; Florian Krammer; Ali H Ellebedy
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

Review 6.  The human antibody response to influenza A virus infection and vaccination.

Authors:  Florian Krammer
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

7.  Broadly protective human antibodies that target the active site of influenza virus neuraminidase.

Authors:  Daniel Stadlbauer; Xueyong Zhu; Meagan McMahon; Jackson S Turner; Teddy J Wohlbold; Aaron J Schmitz; Shirin Strohmeier; Wenli Yu; Raffael Nachbagauer; Philip A Mudd; Ian A Wilson; Ali H Ellebedy; Florian Krammer
Journal:  Science       Date:  2019-10-25       Impact factor: 47.728

8.  Development of Lentiviral Vectors Pseudotyped With Influenza B Hemagglutinins: Application in Vaccine Immunogenicity, mAb Potency, and Sero-Surveillance Studies.

Authors:  Francesca Ferrara; Joanne Marie M Del Rosario; Kelly A S da Costa; Rebecca Kinsley; Simon Scott; Sasan Fereidouni; Craig Thompson; Paul Kellam; Sarah Gilbert; George Carnell; Nigel Temperton
Journal:  Front Immunol       Date:  2021-05-24       Impact factor: 7.561

9.  Development of a Novel Live Attenuated Influenza A Virus Vaccine Encoding the IgA-Inducing Protein.

Authors:  C Joaquín Cáceres; Stivalis Cardenas-Garcia; Aarti Jain; L Claire Gay; Silvia Carnaccini; Brittany Seibert; Lucas M Ferreri; Ginger Geiger; Algimantas Jasinskas; Rie Nakajima; Daniela S Rajao; Irina Isakova-Sivak; Larisa Rudenko; Amy L Vincent; D Huw Davies; Daniel R Perez
Journal:  Vaccines (Basel)       Date:  2021-06-27

10.  Vaccination with a Recombinant H7 Hemagglutinin-Based Influenza Virus Vaccine Induces Broadly Reactive Antibodies in Humans.

Authors:  Daniel Stadlbauer; Arvind Rajabhathor; Fatima Amanat; Daniel Kaplan; Abusaleh Masud; John J Treanor; Ruvim Izikson; Manon M Cox; Raffael Nachbagauer; Florian Krammer
Journal:  mSphere       Date:  2017-12-13       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.